Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Down 6.7% - Time to Sell?

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report)'s share price were down 6.7% during mid-day trading on Friday . The company traded as low as $16.22 and last traded at $16.30. Approximately 9,267 shares traded hands during trading, a decline of 64% from the average daily volume of 25,931 shares. The stock had previously closed at $17.46.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Thursday.

Telix Pharmaceuticals Limited American Depositary Shares Stock Performance

The stock's 50 day moving average is $16.97 and its two-hundred day moving average is $16.93.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA acquired a new position in shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 26,939 shares of the company's stock, valued at approximately $451,000.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.